Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: endovascular radiofrequency ablation and desympathetic nerve surgery.
- Who it may be relevant to
- Registry conditions: Hepatocellular Carcinoma. Basic parameters: 25 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.
Interventions
- Procedure endovascular radiofrequency ablation and desympathetic nerve surgery
endovascular radiofrequency ablation and desympathetic nerve surgery
Primary outcome measures
- ORR [Time frame: every month, up to 1 year]
Secondary outcome measures (2)
- PFS [Time frame: every month, up to 1 year]
- DCR [Time frame: every month, up to 1 year]
Eligibility criteria
Inclusion criteria
- Clinically or pathologically confirmed hepatocellular carcinoma (HCC)
- Locally progressed or distant metastatic unresectable advanced HCC
- Progressed after second-line therapy
- Agree to participate in the study and sign the informed consent form
Exclusion criteria
- Not suitable for ablation surgery
- Pregnant, lactating and planning to become pregnant
- Orthostatic hypotension
- Mixed liver cancer
- Intestinal obstruction
- Obvious bleeding tendencies and hematologic diseases
- Acute or severe systemic infection;
- Stroke or transient ischemic attack (TIA) within two weeks;
- Acute coronary syndrome within two weeks;
- Evaluated to be not suitable for this trial by investigators
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Zhongda Hospital — Nanjing
Identifiers
NCT: NCT06694636 · 2024ZDSYLL167-P01